Volume 26, Number 11—November 2020
Dispatch
Multidrug-Resistant Hypervirulent Group B Streptococcus in Neonatal Invasive Infections, France, 2007–2019
Céline Plainvert, Constantin Hays1, Gérald Touak, Caroline Joubrel-Guyot2, Nicolas Dmytruk, Amandine Frigo, Claire Poyart, and Asmaa Tazi
Table 2
Resistance to erythromycin and high-level resistance to amikacin of GBS neonatal isolates, France, 2007–2019*
| Year | Total GBS isolates, resistance, % (95% CI) |
CC17 GBS, resistance, % (95% CI) |
|||
|---|---|---|---|---|---|
| Erythromycin | Amikacin | Erythromycin | Amikacin | ||
| 2007 | 21.8 (13.0–34.4) | 0.0 (0.0–6.5) | 17.2 (7.6–34.6) | 0.0 (0.0–11.7) | |
| 2008 | 9.0 (4.4–17.4) | 1.3 (0.2–6.9) | 5.1 (1.4–16.9) | 0.0 (0.0–7.7) | |
| 2009 | 19.4 (12.0–30.0) | 1.4 (0.3–7.5) | 7.1 (2.5–19.0) | 0.0 (0.0–9.0) | |
| 2010 | 21.5 (13.9–31.8) | 2.5 (0.7–8.8) | 16.3 (8.5–29.0) | 0.0 (0.0–8.0) | |
| 2011 | 21.7 (13.6–32.8) | 1.5 (0.3–7.8) | 8.6 (3.0–22.4) | 0.0 (0.0–8.8) | |
| 2012 | 10.9 (5.1–21.8) | 3.6 (1.0–12.3) | 5.3 (1.5–17.3) | 2.3 (0.4–11.8) | |
| 2013 | 17.4 (11.6–25.3) | 3.5 (1.4–8.6) | 10.0 (5.2–18.5) | 0.0 (0.0–4.2) | |
| 2014 | 19.1 (12.8–27.4) | 11.8 (7.0–19.2) | 10.7 (5.5–19.7) | 6.5 (3.0–13.5) | |
| 2015 | 25.6 (18.8–33.7) | 14.7 (9.6–21.9) | 23.4 (15.3–34.0) | 10.6 ((5.7–18.9) | |
| 2016 | 18.4 (12.8–25.7) | 11.8 (7.4–18.3) | 20.8 (13.9–30.0) | 8.4 (4.3–15.7) | |
| 2017 | 25.9 (18.7–34.7) | 9.8 (5.6–16.7) | 20.5 (13.0–30.8) | 9.8 (5.0–18.1) | |
| 2018 | 33.1 (25.4–41.7) | 16.9 (11.4–24.5) | 29.7 (21.3–39.7) | 22.4 (14.8–32.3) | |
| 2019 |
29.7 (22.5–38.1) |
18.0 (12.3–25.5) |
28.6 (20.6–38.2) |
14.1 (9.1–21.1) |
|
| p for trend† | 0.019 | <0.0001 | 0.0042 | <0.0001 | |
*CC, clonal complex; GBS, group B Streptococcus. †Evolutionary trends were analyzed using 2-tailed nonparametric Spearman correlation.
1Current affiliation: APHP-Nord (St. Louis) Université de Paris, Paris, France.
2Current affiliation: Le Raincy Hospital, Montfermeil, France.
Page created: August 13, 2020
Page updated: October 19, 2020
Page reviewed: October 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.